Hematopoietic stem cell transplantation for the treatment of autoimmunity in type 1 diabetes.
Type 1 diabetes (T1D) is an autoimmune disease that leads to the destruction of the insulin-producing pancreatic b cells. While there is no current cure, recent work in the field of allogeneic hematopoietic stem cell transplantation (HSCT) and the induction of mixed chimerism, a state in which multilineage hematopoietic populations of both recipient and donor co-exist, has demonstrated that it is possible to provide protection from disease onset, as well as reverse the autoimmune state in spontaneously diabetic mice. Furthermore, the establishment of mixed chimerism induces donor-specific tolerance, providing the potential to normalize glucose regulation via pancreatic islet transplantation without the requirement of life-long immunosuppression. Current studies are aimed at understanding the mechanisms involved in both the reversal of autoimmunity and the induction of tolerance, with the aim of moving this promising approach to curing T1D into the clinic.
Emmanuel College, Boston, Massachusetts 02115, USA.
Samuel A
SA
LoCascio
Joia
J
Spinelli
Josef
J
Kurtz
D000818:Animals; D001324:Autoantigens / Q000276:immunology; D015551:Autoimmunity; D003921:Diabetes Mellitus, Experimental / Q000601:surgery; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D013601:T-Lymphocytes / Q000276:immunology; D019172:Transplantation Conditioning; D014181:Transplantation Immunology; D014182:Transplantation, Autologous; D014183:Transplantation, Heterologous
D001324:Autoantigens